Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
NYSE:BIO
Total Valuation
Bio-Rad Laboratories has a market cap or net worth of $8.14B. The enterprise value is $7.52B.
Market Cap$8.14B
Enterprise Value$7.52B
Share Statistics
Bio-Rad Laboratories has 21,906,399 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding21,906,399
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bio-Rad Laboratories’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is 2.37%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)2.37%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee333.31K
Profits Per Employee-239.51K
Employee Count7,700
Asset Turnover0.27
Inventory Turnover1.56
Valuation Ratios
The current PE Ratio of Bio-Rad Laboratories is ―. Bio-Rad Laboratories’s PEG ratio is -0.03.
PE Ratio―
PS Ratio3.61
PB Ratio1.41
Price to Fair Value1.41
Price to FCF34.82
Price to Operating Cash Flow16.84
PEG Ratio-0.03
Income Statement
In the last 12 months, Bio-Rad Laboratories had revenue of 2.57B and earned -1.84B in profits. Earnings per share was -65.36.
Revenue2.57B
Gross Profit1.38B
Operating Income269.00M
Pretax Income-2.34B
Net Income-1.84B
EBITDA-2.14B
Earnings Per Share (EPS)-65.36
Cash Flow
In the last 12 months, operating cash flow was 491.45M and capital expenditures -154.70M, giving a free cash flow of 336.75M billion.
Operating Cash Flow491.45M
Free Cash Flow336.75M
Free Cash Flow per Share15.37
Dividends & Yields
Bio-Rad Laboratories pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.66
52-Week Price Change-8.17%
50-Day Moving Average314.82
200-Day Moving Average270.98
Relative Strength Index (RSI)40.75
Average Volume (3m)159.55K
Important Dates
Bio-Rad Laboratories upcoming earnings date is Feb 12, 2026, After Close (Confirmed).
Last Earnings DateOct 29, 2025
Next Earnings DateFeb 12, 2026
Ex-Dividend Date―
Financial Position
Bio-Rad Laboratories as a current ratio of 6.48, with Debt / Equity ratio of 20.71%
Current Ratio6.48
Quick Ratio4.85
Debt to Market Cap0.13
Net Debt to EBITDA-0.41
Interest Coverage Ratio5.50
Taxes
In the past 12 months, Bio-Rad Laboratories has paid -498.30M in taxes.
Income Tax-498.30M
Effective Tax Rate0.21
Enterprise Valuation
Bio-Rad Laboratories EV to EBITDA ratio is -4.74, with an EV/FCF ratio of 38.15.
EV to Sales3.96
EV to EBITDA-4.74
EV to Free Cash Flow38.15
EV to Operating Cash Flow22.31
Balance Sheet
Bio-Rad Laboratories has $1.42B in cash and marketable securities with $1.40B in debt, giving a net cash position of $25.30M billion.
Cash & Marketable Securities$1.42B
Total Debt$1.40B
Net Cash$25.30M
Net Cash Per Share$1.15
Tangible Book Value Per Share$207.88
Margins
Gross margin is 52.26%, with operating margin of 10.48%, and net profit margin of -71.86%.
Gross Margin52.26%
Operating Margin10.48%
Pretax Margin-91.27%
Net Profit Margin-71.86%
EBITDA Margin-83.46%
EBIT Margin-89.37%
Analyst Forecast
The average price target for Bio-Rad Laboratories is $357.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$357.50
Price Target Upside18.56% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-0.88%
EPS Growth Forecast10.93%